Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

87.41USD
1:30am IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$87.41
Open
$87.36
Day's High
$87.69
Day's Low
$86.68
Volume
1,527,707
Avg. Vol
1,711,198
52-wk High
$89.69
52-wk Low
$55.10

Chart for

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.51
Market Cap(Mil.): $139,339.80
Shares Outstanding(Mil.): 1,594.09
Dividend: 0.64
Yield (%): 2.93

Financials

  Industry Sector
P/E (TTM): -- 31.16 16.22
EPS (TTM): -- -- --
ROI: -- 14.31 15.23
ROE: -- 15.64 13.84

BRIEF-AbbVie announces positive topline results from phase 3 trial evaluating Venclexta/Venclyxto tablets in combination with Rituxan

* AbbVie announces positive topline results from phase 3 trial evaluating Venclexta™/Venclyxto™ (Venetoclax) tablets in combination with Rituxan® (Rituximab) for the treatment of patients with relapsed/refractory chronic lymphocytic Leukemia

18 Sep 2017

BRIEF-Woodford equity income fund sells Abbvie holding-monthly update

* adds to aa, british land, ip group , lloyds-monthly update Further company coverage:

15 Sep 2017

AbbVie says deaths in arthritis trial not linked to drug

AbbVie Inc said on Monday two patients died in a late-stage trial of its rheumatoid arthritis drug but that the deaths were not linked to the drug, which met the study's main goals.

11 Sep 2017

UPDATE 2-AbbVie says deaths in arthritis trial not linked to drug

Sept 11 AbbVie Inc said on Monday two patients died in a late-stage trial of its rheumatoid arthritis drug but that the deaths were not linked to the drug, which met the study's main goals.

11 Sep 2017

AbbVie reports two patient deaths in rheumatoid arthritis study

Sept 11 AbbVie Inc said on Monday two patients died in a late-stage trial testing its drug to treat patients with moderate to severe rheumatoid arthritis.

11 Sep 2017

BRIEF-AbbVie's upadacitinib meets all primary and ranked secondary endpoints

* AbbVie's upadacitinib (ABT-494) meets all primary and ranked secondary endpoints in second phase 3 study in rheumatoid arthritis

11 Sep 2017

BRIEF-Abbvie Inc says sets quarterly cash dividend of $0.64/shr

* Says ‍board of directors of Abbvie Inc declared a quarterly cash dividend of $0.64 per share​

08 Sep 2017

US STOCKS-Wall St ends flat as media stocks slump, healthcare gains

* Dow down 0.1 pct, S&P down 0.02 pct, Nasdaq up 0.07 pct (Updates to close of U.S. market)

08 Sep 2017

BRIEF-Coherus Biosciences says ‍PTAB denied 4 petitions for inter partes review of Abbvie's patent

* Coherus Biosciences provides update on ‘619 IPR institution decision

07 Sep 2017

AbbVie's positive eczema study drags down Regeneron's shares

AbbVie Inc said on Thursday its experimental drug to treat adults with moderate-to-severe eczema met the main goal in a mid-stage study, dragging down shares of rival U.S. biotech firm Regeneron Pharmaceuticals Inc.

07 Sep 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $131.75 -1.47
Pfizer Inc. (PFE.N) $35.97 -0.02
Novartis AG (NOVN.S) CHF82.95 +0.05
Merck & Co., Inc. (MRK.N) $65.60 -0.19
Roche Holding Ltd. (ROG.S) CHF249.00 +2.00
Roche Holding Ltd. (RO.S) CHF249.00 +1.40
Abbott Laboratories (ABT.N) $51.43 -0.46
Eli Lilly and Co (LLY.N) $83.33 +1.31
Sanofi SA (SASY.PA) €83.87 --

Earnings vs. Estimates